The Innovative Molecular Analysis Technologies Program (IMAT) was established in 1998 to meet the challenge goal of reducing suffering and death due to cancer. IMAT supports research projects aimed at developing creative methods and tools by which to understand, prevent, diagnose, and treat cancer. Through solicitation, outreach, and communication with the investigator community, the IMAT Program has been successful in promoting cancer-relevant applications of a diverse spectrum of new and emerging technologies. more
Innovative and Applied Emerging
Technologies in Biospecimen Science
Sample preparation methods and technologies may be developed for sample collection, processing, isolation, storage, purification, preservation, and, in the case of stored tissues, reversal of adverse events resulting from storage and preservation. more
Application and Use of Transformative
Emerging Technologies in Cancer Research
Emerging Technologies funding opportunities are intended to support projects to evaluate the usefulness of emerging technologies in appropriate biological contexts in order to assess reproducibility and produce preliminary data toward a biological or clinical question. more
Innovative Technology Development for
Cancer Research
IMAT funding opportunities are designed to encourage applications from individuals and groups interested in developing novel technologies suitable for the molecular analysis of cancers and their host environment in support of basic, clinical, and epidemiological research. more
New Related Funding Opportunities
The Innovative Molecular Analysis Technologies (IMAT) program now encompasses an array of 11 closely related Funding Opportunity Announcements (FOAs). Each FOA is segregated based on theme and type of funding mechanism. Click on the links below to view the FOAs by IMAT Program.
2009 IMAT RFAs
The 2009 IMAT Requests For Applications (RFAs) have been published! Application receipt dates for 2009 are as follows: 2/23/09, 5/27/09, and 9/30/09. Interested applicants may access each of the IMAT RFAs by clicking on the funding opportunities tab above or here. Applicants should pay careful attention to the new application requirements stipulated in the RFAs.
As a part of the Biospecimen Research Network of the Office of Biorepositories and Biospecimen Research (OBBR), the IMAT program is pleased to announce the issuance of a new funding opportunity announcement directed at examining the variables associated with human biospecimen integrity: more
The IMAT program is pleased to announce the renewal of this highly successful and competitive technology development initiative.
The program has received approval from both the Executive Committee of the National Cancer Institute as well as its Board of Scientific Advisors for a 5-year continuation of the program and its related funding opportunities. Pursuant to the program's reissuance, new funding opportunities and funding opportunity announcements are currently being planned and synthesized. Additional details will be posted as they become available and all applicants or potential applicants are encouraged to check back soon for details.
